4
Changes in Ownership
TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0001209191-21-009633
Executive VP, Global R&D sold 29,496 shares at $12.69 ($374,437)
- Executive VP, Global R&D acquired 67,852 shares (grant or award)
- Executive VP, Global R&D acquired 16,120 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Fridriksdottir Hafrun · Executive VP, Global R&D
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-02-09 | Exercise or conversion : show line 1 in the form | +16,120 | 61,680.51 | D | ||
| 2021-02-09 | Grant or award : show line 2 in the form | +67,852 | 129,532.51 | D | ||
| 2021-02-09 | Sale : show line 3 in the form | −5,857 | $12.69 | $74,352 | 123,675.51 | D |
| 2021-02-09 | Sale : show line 4 in the form | −23,639 | $12.69 | $300,085 | 100,036.51 | D |
| Open-market sales · 29,496 sh · avg $12.69 · $374,437 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-02-09 | Exercise or conversion : show line 5 in the form Restricted Share Units | −16,120 | 16,121 | D |
| 2021-02-09 | Grant or award : show line 6 in the form Restricted Share Units | +37,884 | 37,884 | D |
Loading xslF345X03/doc4.xml…